No Activity on an Ebola Vaccine: Collplant Founder

The video discusses a company's innovative use of genetically modified tobacco plants to produce human collagen, highlighting its market potential and upcoming products for diabetic foot ulcers and soft tissue repair. The company aims to capture a significant market share in the orthopedic and wound healing sectors, despite challenges from established bovine collagen products. Regulatory considerations and cost competitiveness are also addressed.

What is the significance of the FDA's notice in 2007 regarding collagen products?

What challenges do companies face when introducing new animal-derived collagen products?